🧬 Ehlers-Danlos Syndrome
A group of heritable connective tissue disorders affecting collagen and the body's structural proteins — with 13 distinct subtypes and a wide spectrum of symptoms.
Evidence-based information for patients, caregivers, and healthcare providers worldwide.
What Is Ehlers-Danlos Syndrome?
A heritable connective tissue disorder affecting collagen structure and function
EDS affects the body's connective tissue — the "glue" that holds cells, tissues, and organs together
Connective tissue is found throughout the body, so EDS can affect joints, skin, blood vessels, and internal organs. The underlying cause is abnormal collagen, which makes tissues more fragile, stretchable, and prone to injury. Because symptoms vary widely and overlap with other conditions, many patients wait years for a correct diagnosis.
Genetic Basis
Most EDS subtypes are caused by mutations in genes encoding collagen or collagen-processing enzymes. For example, classical EDS is linked to COL5A1/COL5A2 mutations, vascular EDS to COL3A1 mutations. Hypermobile EDS (hEDS) — the most common — has no confirmed genetic cause yet.
Core Features
The three hallmark features of EDS are: joint hypermobility (joints that move beyond normal range), skin hyperextensibility (skin that stretches unusually), and tissue fragility (easy bruising, poor wound healing, scarring). Severity ranges from mild to life-threatening.
Diagnosis Challenges
EDS is frequently misdiagnosed as fibromyalgia, anxiety, or hypochondria. The diagnostic journey averages 10+ years. Patients often see multiple specialists before receiving the correct diagnosis. Genetic testing confirms most subtypes except hEDS, which relies on clinical criteria.
EDS Subtypes
The 2017 International Classification recognizes 13 subtypes
The most important distinction: vascular EDS (vEDS) is life-threatening
vEDS (COL3A1 mutation) carries risk of spontaneous arterial rupture, bowel perforation, and uterine rupture. Median survival is 48 years. If vEDS is suspected, urgent referral to a vascular specialist is essential. All patients with a family history of young sudden death should be evaluated.
| Subtype | Prevalence | Key Features | Genetic Cause |
|---|---|---|---|
| Hypermobile (hEDS) | ~1:5,000 | Joint hypermobility, chronic pain, POTS, MCAS | Unknown |
| Classical (cEDS) | 1:20,000–40,000 | Skin hyperextensibility, atrophic scarring, joint hypermobility | COL5A1, COL5A2 |
| Vascular (vEDS) | 1:90,000–250,000 | Arterial/bowel/uterine rupture, translucent skin, thin face | COL3A1 |
| Kyphoscoliotic (kEDS) | Very rare | Scoliosis at birth, muscle hypotonia, ocular fragility | PLOD1, FKBP14 |
| Classical-like (clEDS) | Very rare | Similar to cEDS but no atrophic scarring | TNXB |
| Cardiac-valvular (cvEDS) | Very rare | Severe cardiac valve problems, skin and joint features | COL1A2 |
Seven additional rare subtypes exist. Full 2017 classification: The Ehlers-Danlos Society
Diagnosis
Clinical evaluation, genetic testing, and specialist assessment
Beighton Score
A 9-point scale measuring joint hypermobility. Points for: little finger extension >90° (×2), thumb to forearm (×2), elbow hyperextension >10° (×2), knee hyperextension >10° (×2), palms flat on floor knees straight (×1). Score ≥5 suggests generalized joint hypermobility, but the score alone does not diagnose hEDS.
Genetic Testing
For subtypes with known genetic causes (cEDS, vEDS, kEDS, etc.), genetic testing via multigene panel or single-gene sequencing confirms the diagnosis. hEDS has no confirmatory genetic test — it is diagnosed by clinical criteria (2017 criteria require all 3 criteria to be met simultaneously).
Specialist Referrals
Diagnosis typically involves: medical geneticist or clinical genetics team (for genetic testing and subtype confirmation), rheumatologist (joint and pain management), cardiologist (for vEDS or cardiac involvement), physiotherapist (rehabilitation and exercise planning).
hEDS 2017 Diagnostic Criteria
All three criteria must be met: Criterion 1 — Generalized joint hypermobility (Beighton ≥5 or equivalent). Criterion 2 — Two or more of: family history, musculoskeletal complications, or systemic manifestations. Criterion 3 — Absence of unusual skin fragility, exclusion of alternative diagnoses, no causative gene mutation identified. Age- and sex-specific norms apply.
Management
There is no cure for EDS — treatment focuses on symptom management and preventing complications
EDS management is multidisciplinary and highly individualized
Because EDS affects multiple body systems, effective care requires a team including physiotherapy, pain medicine, cardiology (for vEDS), gastroenterology, and often psychology. Early intervention with physiotherapy and joint protection strategies dramatically improves long-term outcomes.
Physiotherapy & Exercise
Proprioception training, joint stability exercises, and low-impact conditioning are the cornerstone of EDS management. Hydrotherapy and Pilates are often recommended. Exercise must be carefully supervised — overstretching can worsen joint instability. Braces and splints protect vulnerable joints during activity.
Pain Management
Chronic pain is the most disabling feature of hEDS. Evidence-based approaches: NSAIDs (short-term), low-dose naltrexone (LDN — emerging evidence), duloxetine or amitriptyline for neuropathic pain, pregabalin, and topical lidocaine. Opioids are generally avoided long-term due to risk of dependence and limited benefit in connective tissue pain.
Orthopedic & Surgical
Surgery for EDS carries significant risk of poor wound healing and tissue failure. It should be a last resort. Joint stabilization surgery (e.g., for unstable shoulder or knee) may be necessary in some cases. Vascular EDS patients require urgent surgical intervention for arterial rupture — celiprolol (beta-blocker) is the only medication shown to reduce vascular events in vEDS (Ong et al., NEJM 2010).
Autonomic & Cardiac Management
For POTS (common in hEDS): increased salt and fluid intake, compression garments, fludrocortisone, midodrine, beta-blockers, or ivabradine. For MCAS: antihistamines (H1+H2), mast cell stabilizers (cromolyn sodium, ketotifen), and trigger avoidance. Regular cardiac monitoring is essential for vEDS and cvEDS patients.
Common Comorbidities
Conditions that frequently co-occur with EDS, especially hEDS
POTS
Postural Orthostatic Tachycardia Syndrome — heart rate increases ≥30 bpm upon standing. Found in up to 78% of hEDS patients in some studies. Symptoms: dizziness, fainting, brain fog, palpitations. Managed with lifestyle changes and medications.
MCAS
Mast Cell Activation Syndrome — mast cells overreact, releasing excessive mediators. Symptoms: flushing, hives, GI problems, anaphylaxis-like reactions. The hEDS-POTS-MCAS triad is increasingly recognized as a distinct clinical entity.
Craniocervical Instability
Instability at the junction of skull and spine — more common in severe hEDS. Symptoms include headaches, neck pain, brain fog, and neurological symptoms. Requires specialist assessment (neurosurgeon familiar with hypermobility disorders).
Gastrointestinal Issues
GI problems affect 60-75% of EDS patients: gastroparesis, irritable bowel, constipation, SIBO. The gut's connective tissue is equally affected. A low-FODMAP diet trial, GI motility medications, and referral to a gastroenterologist experienced with connective tissue disorders is recommended.
Reference: Ehlers-Danlos Society — Comorbidities
Clinical Trials & Research
Current research and open studies worldwide
Finding the genetic cause of hEDS is the field's top priority
The HEDGE study (Hypermobility Ehlers-Danlos Genetic Evaluation) is actively recruiting internationally to identify the genetic basis of hEDS. The Ehlers-Danlos Society coordinates a global research agenda. Patient registries are critical for advancing research in this rare disease field.
HEDGE Study
International multicenter study searching for the genetic cause(s) of hEDS. Collecting genetic samples from patients meeting strict 2017 hEDS criteria. Results expected to transform diagnosis and potentially reveal therapeutic targets. ClinicalTrials.gov
Pain & POTS Trials
Multiple ongoing trials testing: low-dose naltrexone for EDS pain, ivabradine for POTS in EDS, and combined POTS/MCAS management protocols. Search ClinicalTrials.gov for currently recruiting studies.
Celiprolol for vEDS
Celiprolol (beta-blocker) remains the only medication with evidence for reducing vascular events in vEDS. BBEST trial established this. Ongoing research explores other agents (losartan, doxycycline) for vascular protection in collagen disorders.
Lifestyle & Self-Management
Practical strategies for daily life with EDS
Safe Exercise
Low-impact exercise is essential. Best options: swimming, hydrotherapy, cycling (stationary), Pilates (with experienced instructor), tai chi. Avoid high-impact activities, heavy lifting, and extreme stretching. Start slowly, build gradually, always use joint protection strategies.
Nutrition
Anti-inflammatory diet may help with pain and fatigue. Adequate vitamin C intake supports collagen synthesis. For MCAS: low-histamine diet. For POTS: high salt (8-10g/day) and high fluid intake (2-3L/day). Magnesium may help with muscle pain and sleep.
Sleep & Energy
Fatigue is one of the most disabling EDS symptoms. Good sleep hygiene, consistent sleep schedule, and addressing underlying causes (pain, POTS, sleep apnea) are essential. Pacing — balancing activity and rest — is a key self-management skill for avoiding post-exertional malaise.
Joint Protection
Braces, splints, and supports protect vulnerable joints. Adaptive equipment reduces strain on hands and wrists. Occupational therapy assessments provide personalized recommendations for workplace and home modifications. Medical alert bracelets are recommended for vEDS patients.
Mental Health & Wellbeing
The psychological impact of living with a chronic, often invisible illness
Medical gaslighting is a significant trauma for EDS patients
Many patients report being told their symptoms are "just anxiety," "all in your head," or that they are exaggerating. This diagnostic invalidation causes lasting psychological harm. Connecting with EDS-aware healthcare providers and peer communities is transformative for mental health outcomes.
Cognitive Behavioral Therapy (CBT)
CBT adapted for chronic pain helps patients manage pain catastrophizing, sleep difficulties, and activity avoidance. Evidence supports CBT for reducing the disability impact of chronic pain — not by dismissing it, but by changing how the brain processes persistent pain signals.
Peer Support
The EDS community is large and highly active online. Patient-to-patient support provides practical coping strategies, validation, and information about experienced clinicians. The Ehlers-Danlos Society facilitates peer support programs globally.
International Resources
Patient organizations, specialist networks, and information hubs
The Ehlers-Danlos Society
The primary global patient organization for EDS and hypermobility spectrum disorders. Provides the 2017 diagnostic criteria, clinician database, research funding, and patient community. Global reach with chapters across North America, Europe, and beyond.
ehlers-danlos.comHypermobility Connect (UK)
UK-based charity supporting people with hypermobility-related conditions including hEDS. Provides peer support, information resources, and advocacy for better NHS recognition and care.
hypermobilityconnect.orgRare Voices Australia / EDS Australia
Patient advocacy for EDS in Australia. Supports the EDS community with information, events, and connection to specialist clinicians.
edsaus.org.auFind an EDS Specialist
The Ehlers-Danlos Society maintains a healthcare provider directory. Always verify that a provider has experience with EDS — general rheumatologists or orthopedic surgeons without EDS experience may give harmful advice.
Find a ProviderMore CarePedia Portals
Evidence-based information portals for complex and rare conditions worldwide.
Browse All Portals →